



About Us


ProBioVet applies modern genetic engineering techniques to the development of bioprocesses to obtain recombinant proteins for a variety of uses in veterinary medicine, industry and agriculture.

Business Line

Our main business line is focused on controlling **cattle ticks** and other ectoparasites by using vaccination.

Over 1 billion heads of cattle are exposed to tick infestations worldwide. There is a potential market of about 3bn dollars per year for anti-tick vaccines.

Vaccination affects the life cycle of ticks



Vaccines based on rBm86 and BM95-MSP1a antigens **reduce** cattle management **costs more than 50%**.

The initial opportunity to sell vaccines against ticks has been explored in Latin American countries where more than 300 million heads of cattle are exposed to tick infestations.

Products

ProBioVet sells the antigens **rBm86** and **BM95-MSP1a** to be used in vaccines against the cattle tick *Rhipicephalus (Boophilus) microplus*.

The company also **licenses technologies** to produce:

- rBm86 and other secreted proteins in a *Pichia pastoris* strain
- BM95-MSP1a and a wide range of peptides exposed on the surface of a recombinant *Escherichia coli* strain

Contact:

Mario Canales
General Manager
+34 926 213 794
mario.canales@probiovet.com
<http://www.proteinalternatives.com/>



Partnering Opportunity

Services

Our company designs and develops new bioprocesses to obtain recombinant proteins upon request.

We also offer technical assistance in optimization of current biotechnological processes.



Intellectual Property

ProBioVet owns an expression system that utilizes peptides of a fragment of the MSP1a protein from *Anaplasma marginale*. This system allows for protein expression exposed on *E. coli*.

An exclusive license of the patent for this expression system has been granted to ProBioVet (PCT/ES2009/070103, Priority date: 04/16/2008).

R&D Portfolio

ProBioVet is now working on new projects to develop:

- New formulations of the cattle tick vaccine;
- New ectoparasites vaccines for the control of *Dermanysus gallinae* infestations in poultry; and
- New technologies to produce:
 - bioethanol from thermotolerant yeast,
 - biopolymers from recombinant bacteria to be used in the spinal cord repairs after injuries.

Our company has been granted research loans and funding from public sources (389,000.00 € from MICINN).

Business Opportunity

ProBioVet is seeking partners interested in **licensing-in** our technologies to produce the antigens or in **launching** anti-tick vaccines in Latin American countries.

Financial Opportunity

ProBioVet seeks **additional funding** to accelerate the **development** of the projects we are working on and to introduce our products and technologies in the market of Latin America.

Contact:

Anna Riera
Project Manager
+34 914 491 250 EXT 034
anna.riera@gen-es.org
<http://www.gen-es.org/>

